HGH and Trenbolone Interaction: Monitor | Peptide Database

FDA-approved for reduction of elevated total cholesterol and LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with a statin. Reduces LDL by approximately 18% as monotherapy and provides an additional 25% reduction when added to ongoing statin therapy. Widely used off-label by anabolic steroid users to counteract the significant lipid disturbances caused by AAS, particularly oral 17-alpha-alkylated steroids. Oral compounds like oxandrolone can reduce HDL by 50% or more and elevate LDL substantially. Ezetimibe helps blunt LDL elevation while its non-hepatotoxic profile makes it preferable to statins during cycles involving liver-stressing orals. When LDL targets are not achieved with statin monotherapy, adding ezetimibe provides a complementary mechanism of action. The IMPROVE-IT trial demonstrated that the combination of ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-acute coronary syndrome patients. The IMPROVE-IT trial established that adding ezetimibe to simvastatin therapy reduced the composite endpoint of cardiovascular death, major coronary events, and stroke by 6.4% over 7 years in patients with recent acute coronary syndrome. This was the first trial to demonstrate that a non-statin LDL-lowering agent provides incremental cardiovascular benefit. Approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH) in combination with statins. Also used in heterozygous FH when statin monotherapy is insufficient to reach LDL targets. Particularly useful in patients who cannot tolerate high-dose statins.

Join others researching Phenylpiracetam — share findings, ask questions, and learn from real experiences Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia. Phenylpiracetam modulates multiple neurotransmitter systems, which accounts for its broad spectrum of cognitive and physical effects. Like other racetams, it acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic transmission and facilitating long-term potentiation in hippocampal circuits critical for memory formation. However, unlike piracetam, phenylpiracetam also significantly affects dopaminergic and noradrenergic signaling -- it increases the density of dopamine D1, D2, and D3 receptors and noradrenaline receptors in the striatum and other brain regions, which underpins its stimulant, mood-elevating, and motivation-enhancing properties. It also modulates nicotinic acetylcholine receptors and NMDA-type glutamate receptors, contributing to its procognitive effects. The phenyl group increases lipophilicity, allowing faster and more complete penetration of the blood-brain barrier compared to piracetam. Phenylpiracetam also demonstrates anticonvulsant activity and has been shown to reduce the threshold for cold-induced stress responses, likely through modulation of hypothalamic thermoregulatory circuits and peripheral adrenergic mechanisms. The compound's physical performance-enhancing effects are attributed to increased noradrenergic and dopaminergic tone, enhanced muscular endurance, and reduced perception of effort and fatigue.